Compare · BON vs DFTX
BON vs DFTX
Side-by-side comparison of Bon Natural Life Limited (BON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.72B, about 509.2x BON ($9.3M).
- DFTX has hit the wire 9 times in the past 4 weeks while BON has been quiet.
- DFTX has more recent analyst coverage (8 ratings vs 0 for BON).
- Company
- Bon Natural Life Limited
- Definium Therapeutics Inc.
- Price
- -
- -
- Market cap
- $9.3M
- $4.72B
- 1M return
- -
- +0.20%
- 1Y return
- -
- +183.50%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 8
Latest BON
- SEC Form 6-K filed by Bon Natural Life Limited
- SEC Form 3 filed by new insider Zhixiang Gao
- SEC Form 3 filed by new insider Chen Jing Veronica
- SEC Form 3 filed by new insider Hu Yongwei
- SEC Form 3 filed by new insider Xue Yingchun
- SEC Form 3 filed by new insider Ma Xin
- SEC Form 3 filed by new insider Wenjuan Chen
- SEC Form 3 filed by new insider Liu Jing
- SEC Form 3 filed by new insider Gao Jianjun
- BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
Latest DFTX
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress
- Definium Therapeutics to Participate at Upcoming Investor Conferences
- Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Announces New Employee Inducement Grants